EAACI Congress 2025
BackL-TPS07 - Biologicals 04
Friday 13 Jun, 12:00 PM -
13:00 PM Glasgow, United Kingdom
Poster Zone
Thematic Poster Session
D1.374
"The Role of Atopy Biomarkers in Predicting Dupilumab Response in Moderate to Severe Atopic Dermatitis: A Single Center Retrospective Study"
D1.379
AllergoOncology: Generation of Equinized Anti-PD-L1 mAbs with Specific Equine Constant Regions by MOE-PCR Ligation-Independent Cloning (LIC)
D1.377
Berotralstat effectively controls a type 2 Hereditary Angioedema patient, refractory to other long-term prophylaxis treatments – Case report
D1.385
Dupilumab Treatment Effects on Atopic Manifestations in Patients with Inborn Errors of Immunity
D1.376
Emerging inmunomodulatory agents for atopic dermatitis
D1.378
Evaluating the efficacy of dupilumab treatment for atopic dermatitis across geographic areas: A systematic review and meta-regression analysis
D1.386
Impact of dupilumab on allergen specific immunoglobulin E production
D1.384
Long-term Prophylaxis with Lanadelumab in Hereditary and Acquired Angioedema: A Single-Center Retrospective-Prospective “Real-Life” Analysis
D1.383
Nonimmediate hypersensitivity reaction to Lanadelumab in a patient with Hereditary Angioedema: a case report
D1.372
Potential blood biomarkers of disease activity in patients with chronic spontaneous urticaria
D1.380
Quicker EASI 75 or greater decline of DLQI - is it significant? Comparison of dupilumab treatment among children and adults in two centres in Cracow
D2.93
Differential effects of dupilumab in women with severe uncontrolled asthma
D2.364
Omalizumab Use in Pediatric Chronic Urticaria, A Retrospective Study from a Tertiary Hospital
